Transforming Rectal Cancer Care: Upfront Surgery Wins

Selected rectal cancer patients can safely skip neoadjuvant therapy and proceed directly to total mesorectal excision.

Among 94 patients, 100% had local recurrence-free survival at 3 years; 97% at 5 years.
R0 resection achieved in 99%, leading to substantial overall survival rates of 97% at 3 years and 95% at 5 years.

This evidence supports refining patient selection for surgery, minimizing unnecessary preoperative treatment while maintaining excellent outcomes.

87% distant metastasis-free survival at 3 years; 81% at 5 years underscores the effectiveness of this approach.

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Intestine and Lower Gastrointestinal Tract.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

More in Intestine and Lower Gastrointestinal Tract

Ann Surg Oncol2 Nov 2026

Patients smoking at diagnosis were less likely to have a favorable response to treatment before rectal cancer surgery; former smokers were not.

JAMA Surg30 Oct 2026

For severe slow-transit constipation, removing less colon gave similar symptom relief at one year, with less early incontinence.

Surg Endosc29 Oct 2026

In low rectal cancer surgery, removing the specimen through the anus was linked to fewer wound complications and less pain in the first two days.